Navigation Links
The Role of Central Laboratories in Alzheimer’s Disease Research, a New Global Cliniacal Trials Webinar Hosted by Xtalks
Date:11/18/2013

Toronto, Canada (PRWEB) November 18, 2013

Recently, major changes were made in the diagnostic criteria for Alzheimer’s disease and encompass the latest findings in the field, which is helping to facilitate more clinical research. Already, the usual clinical interview can be coupled with brain imaging testing approved by the FDA for the diagnosis of Alzheimer’s disease in live patients. Several disease-modifying or disease-preventing therapies are also appearing in clinical trials. Central laboratories can play a key role in clinical trials for Alzheimer’s disease drug development by assisting with patient population identification and by detecting, at an early stage, drugs that are likely to fail, leading to important time and costs savings.

Join us for this webinar that will be addressing how central laboratories can support clinical trials through quality testing within the context of the latest advances in Alzheimer’s disease research.

For more information about this online seminar or to visit this webinar’s homepage, go to http://xtalks.com/central-laboratories-in-alzheimers-research.ashx.

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year, thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://www.xtalks.com.

Contact:
Michelle Tran, Marketing Manager
+1 (416) 977-6555 ext 284
mtran(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/11/prweb11335913.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. LabCentral Adds Eppendorf as a Major Sponsor of the Cambridge Launchpad for Life Science Startups
2. The Arrow Group of Animal Hospitals in Central Arizona Partners with Vet-Stem, Inc. to Bring Stem Cell Therapy to Their Patients
3. ResearchMoz.us: Private Healthcare Market - Investigation, Study, Size, Share in Central Europe and Poland and Poland 2013
4. Congresso ESH 2013, dallo studio SEVITENSION nuove evidenze sullefficacia della combinazione fissa olmesartan/amlodipina vs. perindopril/amlodipina nel controllo della pressione arteriosa centrale
5. Endpoint Based Protocol Development: A Central Laboratory Perspective + Microbiology Case Study, New Life Science Webinar Hosted by Xtalks
6. Central Nervous System (CNS) Biomarkers Market: 2017 Forecast in New Research Report at ReportsnReports.com
7. Site Quality Management to Optimize Risk-Based and Centralized Monitoring, New Life Science Webinar Hosted by Xtalks
8. ‘Timely’ new undergrad program in photonics at University of Central Florida applauded by SPIE
9. BioHealth Innovation, Inc. Forms Commercial Relevance Advisory Board to Help Advance Market-Relevant Innovations in Central Maryland
10. Florida-Based Team Gemini Signs Recycling Facility Agreement with Solid Waste Authority of Central Ohio
11. Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):